Elypta is a molecular diagnostic company focused on preventing cancer mortality by developing a liquid biopsy platform for detection and monitoring of the disease. The approach is based on measurement of the complete profile of human glycosaminoglycans as biomarkers of tumor metabolism and use of machine learning algorithms to generate a score against cancer-type specific signatures. Studies have shown exceptional accuracy in renal cell carcinoma and the clinical development program include multiple other indications.
Potential applications include early detection, surveillance of recurrence and monitoring or prediction of treatment response, replacing or complementing medical imaging. Elypta is differentiated by its pan-cancer potential, metabolism-based approach and robust, cost-efficient mass-spectrometry based kits. Several years of research at Chalmers University of Technology in Gothenburg, Sweden, led to the founding of Elypta in the spring of 2017